<?xml version='1.0' encoding='ISO-8859-1'?>
<xml>
<title>Illinois General Assembly - Bill Status for HB 3630         </title>
<shortdesc>INS-PHARMACY BENEFIT MANAGERS</shortdesc>
<sponsor>
<sponsorhead1>House Sponsors</sponsorhead1><sponsors>Rep. Greg Harris-Sue Scherer-C.D. Davidsmeyer-Dan Caulkins, Bob Morgan, Jonathan Carroll, Deb Conroy, Anna Moeller, Ann M. Williams, Nicholas K. Smith, Mark L. Walker, Patrick Windhorst, Curtis J. Tarver, II, Robyn Gabel, Thomas M. Bennett, Brad Halbrook, Tim Butler, Janet Yang Rohr, Daniel Swanson, Dan Brady, Dave Severin, Chris Miller, Barbara Hernandez, Jehan Gordon-Booth, Charles Meier, Stephanie A. Kifowit, David Friess, Amy Grant, Bradley Stephens, Delia C. Ramirez, Mike Murphy, Anthony DeLuca and Amy Elik</sponsors>
</sponsor>
<lastaction>
<statusdate>1/10/2023</statusdate><chamber>House</chamber><action>Session Sine Die</action>
</lastaction>
<synopsis>
<synopsistitle></synopsistitle>
<reference>215 ILCS 5/155.37</reference><aliasreference></aliasreference><reference>215 ILCS 5/424</reference><aliasreference>from Ch. 73, par. 1031</aliasreference><reference>215 ILCS 5/513b1</reference><aliasreference></aliasreference><reference>215 ILCS 5/513b1.1 new</reference><aliasreference></aliasreference><reference>215 ILCS 5/513b1.3 new</reference><aliasreference></aliasreference><reference>305 ILCS 5/5-5.12</reference><aliasreference>from Ch. 23, par. 5-5.12</aliasreference><reference>305 ILCS 5/5-36</reference><aliasreference></aliasreference><SynopsisText>     Amends the Illinois Insurance Code. Provides that if a generic equivalent for a brand name drug is approved by the federal Food and Drug Administration, plans that provide coverage for prescription drugs through the use of a drug formulary that are amended, delivered, issued, or renewed in the State on or after January 1, 2022 shall comply with specified requirements. Provides that the Department of Insurance may adopt rules to implement provisions concerning notice of change of drug formulary. In provisions concerning a contract between a health insurer and a pharmacy benefit manager, provides that a pharmacy benefit manager must update and publish maximum allowable cost pricing information according to specified requirements, must provide a reasonable administrative appeal procedure to allow pharmacies to challenge maximum allowable costs, and must comply with specified requirements if an appeal is denied. Sets forth provisions concerning pharmacy benefit manager contracts; specified requirements that a pharmacy benefit manager shall comply with; and specified requirements that an auditing entity shall comply with when conducting a pharmacy audit. Provides that a violation of specified provisions is an unfair method of competition and unfair and deceptive act or practice in the business of insurance. Sets forth provisions concerning applicability of the Pharmacy Benefit Managers Article of the Illinois Insurance Code, and provisions concerning fiduciary responsibility of a pharmacy benefit manager. Defines terms. Makes other changes. Amends the Illinois Public Aid Code. Sets forth provisions concerning reimbursement of professional dispensing fees and acquisition costs for pharmacy providers.</SynopsisText></synopsis>
<actions>
<statusdate>2/19/2021</statusdate><chamber>House</chamber><action>Filed with the Clerk by Rep. Greg Harris</action>
<statusdate>2/22/2021</statusdate><chamber>House</chamber><action>First Reading</action>
<statusdate>2/22/2021</statusdate><chamber>House</chamber><action>Referred to Rules Committee</action>
<statusdate>3/4/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Bob Morgan</action>
<statusdate>3/8/2021</statusdate><chamber>House</chamber><action>Added Chief Co-Sponsor Rep. Sue Scherer</action>
<statusdate>3/10/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Jonathan Carroll</action>
<statusdate>3/10/2021</statusdate><chamber>House</chamber><action>Added Chief Co-Sponsor Rep. C.D. Davidsmeyer</action>
<statusdate>3/10/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Deb Conroy</action>
<statusdate>3/10/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Anna Moeller</action>
<statusdate>3/10/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Ann M. Williams</action>
<statusdate>3/10/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Nicholas K. Smith</action>
<statusdate>3/10/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Mark L. Walker</action>
<statusdate>3/12/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Patrick Windhorst</action>
<statusdate>3/12/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Curtis J. Tarver, II</action>
<statusdate>3/16/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Robyn Gabel</action>
<statusdate>3/16/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Thomas M. Bennett</action>
<statusdate>3/16/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Brad Halbrook</action>
<statusdate>3/16/2021</statusdate><chamber>House</chamber><action>Assigned to Prescription Drug Affordability &amp; Accessibility Committee</action>
<statusdate>3/16/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Tim Butler</action>
<statusdate>3/16/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Janet Yang Rohr</action>
<statusdate>3/17/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Daniel Swanson</action>
<statusdate>3/18/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Dan Brady</action>
<statusdate>3/18/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Dave Severin</action>
<statusdate>3/18/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Chris Miller</action>
<statusdate>3/22/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Barbara Hernandez</action>
<statusdate>3/24/2021</statusdate><chamber>House</chamber><action>Added Chief Co-Sponsor Rep. Dan Caulkins</action>
<statusdate>3/24/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Jehan Gordon-Booth</action>
<statusdate>3/24/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Charles Meier</action>
<statusdate>3/26/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Stephanie A. Kifowit</action>
<statusdate>3/27/2021</statusdate><chamber>House</chamber><action>Rule 19(a) / Re-referred to Rules Committee</action>
<statusdate>3/29/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. David Friess</action>
<statusdate>3/29/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Amy Grant</action>
<statusdate>4/1/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Bradley Stephens</action>
<statusdate>4/14/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Delia C. Ramirez</action>
<statusdate>4/21/2021</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Mike Murphy</action>
<statusdate>1/5/2022</statusdate><chamber>House</chamber><action>Assigned to Prescription Drug Affordability &amp; Accessibility Committee</action>
<statusdate>1/7/2022</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Anthony DeLuca</action>
<statusdate>1/31/2022</statusdate><chamber>House</chamber><action>Added Co-Sponsor Rep. Amy Elik</action>
<statusdate>2/18/2022</statusdate><chamber>House</chamber><action>Rule 19(a) / Re-referred to Rules Committee</action>
<statusdate>1/10/2023</statusdate><chamber>House</chamber><action>Session Sine Die</action>
</actions>
</xml>

